We describe an improved method of detecting anti-granulocyte antibodies utilizing radiolabeled staphylococcal protein A (SPA). The results of this SPA assay were compared to data obtained with leukoagglutination tests and granulocyte indirect immunofluorescence techniques. We have shown that the SPA assay is highly sensitive and reproducible. In addition, absorption studies confirmed that the assay is specific for granulocytes. The SPA assay is performed in microtiter plates, and requires significantly fewer granulocytes and less test sera than previously described techniques. Also, we have shown that granulocytes prepared for this assay can be separated and stored for up to 48 h. Therefore, the SPA assay described herein is particularly useful for screening of sera and is one of the most sensitive assays available for detecting anti-granulocyte antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0022-1759(84)90130-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraoperative comparison of Y-shape cannula and concentric needle techniques in single-puncture temporomandibular joint arthrocentesis.
J Craniomaxillofac Surg
January 2025
Department of Oral and Maxillofacial Surgery, Dentistry, Adıyaman University, 02030, Adıyaman, Turkey. Electronic address:
This study aims to compare two different single-puncture arthrocentesis (SPA) Type 2 techniques, the Y-shaped cannula and the concentric needle methods, in terms of intraoperative parameters. In the study, data from 32 unilateral temporomandibular joint (TMJ) arthrocentesis procedures, including procedure duration (seconds), the number of cannula relocations, and procedural difficulty (evaluated using a visual analog scale), were retrospectively analyzed. The Y-shaped cannula technique was found to significantly reduce procedure duration (284.
View Article and Find Full Text PDFPrediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study.
RMD Open
January 2025
Rheumatology and Translational Immunology Research Laboratories (LaRIT), Department of Internal Medicine and Therapeutics, Universita di Pavia, Pavia, Italy.
Objective: To delineate, within the framework of current clinical practice and criteria, the sustainability of first-line immuno-suppressive treatment discontinuation in rheumatoid arthritis (RA) and the impact of residual disease in remission on long-term drug-free (DF) outcomes.
Methods: RA patients, referring to the Pavia early arthritis clinic (EAC) between 2009 and 2021 and achieving remission after Disease Activity Score-driven methotrexate (MTX) monotherapy, were recruited. Eligible patients underwent DF follow-up at 3-month intervals over 5 years after MTX discontinuation.
Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.
BMC Chem
January 2025
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
For paediatric patients suffering from neurofibromatosis, Selumetinib (SEL) is the only approved drug. Here an original ecofriendly and high pace method is introduced using 96- microwell spectrophotometric assay (MW-SPA) to measure SEL content in bulk and commercial pharmaceutical formulation (Koselugo capsules). This assay was relied on in-microwell formation of a coloured charge transfer complex (CTC) upon interaction of SEL with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ).
View Article and Find Full Text PDFPerformance of spondyloarthritis-specific health utilities based on ASAS Health Index: an ancillary analysis from ASAS-HI validation study.
Rheumatology (Oxford)
January 2025
Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany.
Objectives: To compare the utility values of Spondyloarthritis (SpA)-specific ASAS Health Index (U-ASAS-HI) to generic utilities and to understand the contribution of health outcomes, personal- and country-level factors to the U-ASAS-HI.
Methods: Ancillary analysis of the ASAS-HI international validation study. SpA patients who completed the ASAS-HI, 5-level EuroQol-5D (EQ-5D-5L) and Short Form-36 (SF-36) questionnaires were selected, and utilities calculated.
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.
ESMO Open
January 2025
Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, (Milan), Italy. Electronic address:
Background: The treatment of advanced hepatocellular carcinoma (HCC) with atezolizumab and bevacizumab led to significant improvements in overall survival (OS), progression-free survival (PFS), and response rate compared with sorafenib in the phase III IMbrave150 trial. The etiology of background liver disease can differ between Eastern and Western populations, leading to a potentially different impact of systemic therapies; therefore the unequal representation must be considered in the IMbrave150 trial. To provide further data on the safety and effectiveness of atezolizumab and bevacizumab, the phase IIIb AMETHISTA (Atezolizumab plus bevacizumab in METastatic HCC Italian Safety TriAl) ran in a Western (Italian) population of patients with advanced HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!